Ray-Coquard I et al. - In an investigation of the use of gefitinib in refractory advanced synovial sarcomas (SyS), it was shown that gefitinib monotherapy in advanced SyS refractory to conventional chemotherapy did not demonstrate sufficient activity to warrant further investigation in this setting, suggesting that HER-1 is not a critical protein in tumor progression in this disease Methods
Gefitinib was given at a 500-mg/day oral dose until progression or intolerance
Results
48 pts were included; all pts had previously received chemotherapy for metastatic disease, with a median number of 2 lines
The most frequent metastatic sites were the lungs, lymph nodes, and soft tissues
Median duration of treatment was 43 days; treatment was interrupted in 5 pts; treatment was halted for progression in 45 pts
The best response was stable disease in 10 pts
Disease progression occurred in 32 pts, with a median time to disease progression of 6 weeks
Progression-free survival at 4 and 6 months was 21% and 6%, respectively
See all
